Capillarisin

Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties. Capillarisin can be used for the research of asthma-mediated complications and can be a potential neuroprotectant against bupivacaine-induced neurotoxicity^[1][2][3]. In Vitro: Capillarisin (0~40 μM; 24 hours; SH-SY5Y cells) does not produce any significant changes on the viability of SH-SY5Y cells^[3].
. Capillarisin (40 μM; 24 hours; SH-SY5Y cells) induces PI3K/PKB pathway inactivation, which inhibiting apoptosis in bupivacaine-challenged SH-SY5Y cells is overturned by LY294002 treatment and counteracts bupivacaine-induced injury via activating the PI3K/PKB pathway^[3].
. Capillarisin antagonizes bupivacaine-induced oxidative stress via activating the PI3K/PKB pathway in SH-SY5Y cells. Capillarisin inhibits bupivacaine-induced mitochondrial injury and endoplasmic reticulum stress via activating PI3K/PKB pathway^[3]. In Vivo: Capillarisin (20 and 80 mg/kg; i.p.; 1 hour) pretreatment strongly inhibits NF-κB mediated genes (iNOS, COX-2)^[4].
Capillarisin significantly reduces the plasma leading nitrite production. Capillarisin markedly suppresses the adenosine 5'-triphosphate (ATP) in plasma and substance P in CFA-induced paw tissue^[4].